secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001809519-24-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q4 revenue $196.6M; net loss $25.9M; adj. EBITDA $57.3M
--------------------------------------------------------------

- Q4 2023 revenue $196.6M, net loss $25.9M (13.2% margin), adjusted net income $31.1M (15.8% margin).
- Full year 2023 revenue $750.3M, net loss $8.9M, adjusted EBITDA $217.4M (28.6% margin).
- Q4 net cash from operations $15.9M; exited with over 7M consumers of prescription offerings.
- Interim CEO Scott Wagner expects continued topline growth in Q1 and full year 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000029/0001809519-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000029/gdrx-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001809519-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer